MicroRNA-891b is an independent prognostic factor of pancreatic cancer by targeting Cbl-b to suppress the growth of pancreatic cancer cells
Metrics: PDF 1509 views | HTML 1078 views | ?
Qian Dong1, Ce Li2, Xiaofang Che2, Jinglei Qu2, Yibo Fan2, Xiaohan Li3, Yue Li3, Qian Wang4, Yunpeng Liu2, Xianghong Yang3, Xiujuan Qu2
1Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, 110004, China
2Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, 110001, China
3Department of Pathology, Shengjing Hospital of China Medical University, Shenyang, 110004, China
4Department of Medical Oncology, The Liaoning Provincial Tumor Hospital, Shenyang, 110042, China
Xianghong Yang, email: email@example.com
Xiujuan Qu, email: firstname.lastname@example.org
Keywords: pancreatic ductal adenocarcinoma (PDAC), microRNA-891b (miR-891b), Cbl-b, prognosis, overall survival (OS)
Received: December 27, 2015 Accepted: June 01, 2016 Published: August 02, 2016
Growing evidence has revealed that microRNAs could regulate the proliferation of pancreatic ductal adenocarcinoma (PDAC) cells and predict the prognosis of PDAC. Here the comparative microRNA expression profiles of the good and poor prognosis groups were performed by microRNA microarray. MicroRNA-891b (miR-891b) was screened and validated to be a prognostic predictor of PDAC in the initial group and further evaluated to be an independent predictor for the overall survival of resectable PDACs in an independent cohort. By a series of cellular and animal experiments, as well as clinical specimen analyses, miR-891b was confirmed to target the Cbl-b gene, promot the expression of tumor suppressor p21 protein and inhibit the proliferation of PDAC cells. The results provide a theoretical basis for the study of miR-891b as an independent prognostic predictor of PDAC and the role of miR-891b/Cbl-b pathway in this prediction, as well as the identification of new targets for PDAC.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.